Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: SpectraCure AB

Market Cap 3.02Cr 32.05L 27.67L 25.51L 23.92L 44.81L 30Cr 45.46L 1.18Cr 15Cr 1.2Cr 1.18Cr 52Cr P/E Ratio 2024
-10.6x
P/E Ratio 2025 -0.79x
Enterprise Value 1.95Cr 20.67L 17.85L 16.46L 15.43L 28.9L 20Cr 29.32L 75.82L 9.56Cr 77.57L 75.92L 33Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.17%
Yield 2024 *
-
Yield 2025 -
1 day-55.39%
1 week-62.14%
Current month-62.14%
1 month-17.06%
3 months-42.39%
6 months-69.19%
Current year-65.98%
1 week 0.04
Extreme 0.0438
0.14
1 month 0.04
Extreme 0.0438
0.17
Current year 0.04
Extreme 0.0438
0.17
1 year 0.04
Extreme 0.0438
0.38
3 years 0.04
Extreme 0.0438
6.59
5 years 0.04
Extreme 0.0438
13.19
10 years 0.04
Extreme 0.0438
45.15
Manager TitleAgeSince
Chief Executive Officer 54 01/10/2025
Director of Finance/CFO - 01/06/2026
Chief Tech/Sci/R&D Officer - 07/10/2025
Director TitleAgeSince
Director/Board Member 63 31/08/2012
Director/Board Member 72 01/01/2022
Chairman 74 01/01/2022
Date Insider Type Main position Quantity % Market Cap.
26/23/26Buy

Chairman

25,000 0.0257%
30/22/30Buy

Director

25,000 0.0257%
09/22/09Buy

Director

10,48,493 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
-55.39%-62.14%-84.94%-99.17% 32.18L
-1.44%+5.65%+55.72%+42.51% 152.74Cr
+0.14%-3.64%-24.39%-39.51% 33Cr
+0.88%-2.98%-1.72%-50.43% 5.61Cr
Average -13.95%-15.78%-13.83%-36.65% 47.97Cr
Weighted average by Cap. -1.19%+3.68%+39.95%+25.37%

Financials

2024 2025
Net sales - -
Net income -2.3Cr -24.38L -21.05L -19.41L -18.2L -34.08L -23Cr -34.58L -89.42L -11Cr -91.48L -89.53L -39Cr -5.61Cr -59.43L -51.31L -47.31L -44.36L -83.09L -57Cr -84.29L -2.18Cr -27Cr -2.23Cr -2.18Cr -96Cr
Net Debt -1.31Cr -13.91L -12.01L -11.08L -10.39L -19.45L -13Cr -19.73L -51.04L -6.43Cr -52.21L -51.1L -22Cr -1.07Cr -11.38L -10L -9L -8L -15.91L -11Cr -16.14L -41.73L -5.26Cr -42.69L -41.78L -18Cr
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
12/26/12 0.0530 kr -55.39% 2,95,51,190
11/26/11 0.1188 kr -2.14% 10,17,910
10/26/10 0.1214 kr -5.75% 14,24,137
09/26/09 0.1288 kr -0.46% 4,09,484
08/26/08 0.1294 kr -7.57% 24,87,295
  1. Stock Market
  2. Stocks
  3. SPEC Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!